208 related articles for article (PubMed ID: 37553911)
1. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Oner G; Broeckx G; Van Berckelaer C; Zwaenepoel K; Altintas S; Canturk Z; Tjalma W; Berneman Z; Peeters M; Pauwels P; van Dam PA
Cancer Med; 2023 Sep; 12(17):17901-17913. PubMed ID: 37553911
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
3. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
López-Velazco JI; Manzano S; Otaño M; Elorriaga K; Bultó N; Herrero J; Lahuerta A; Segur V; Álvarez-López I; Caffarel MM; Urruticoechea A
Breast Cancer Res; 2024 Jan; 26(1):3. PubMed ID: 38173005
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer.
Brechbuhl HM; Xie M; Kopin EG; Han AL; Vinod-Paul K; Hagen J; Edgerton S; Owens P; Sams S; Elias A; Sartorius CA; Tan AC; Kabos P
Mol Carcinog; 2022 Mar; 61(3):359-371. PubMed ID: 34856027
[TBL] [Abstract][Full Text] [Related]
5. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract][Full Text] [Related]
6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
8. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
Cabioglu N; Onder S; Oner G; Karatay H; Tukenmez M; Muslumanoglu M; İgci A; Eralp Y; Aydiner A; Saip P; Yavuz E; Ozmen V
BMC Cancer; 2021 Apr; 21(1):357. PubMed ID: 33823818
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
10. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
11. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
12. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP
Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143
[TBL] [Abstract][Full Text] [Related]
13. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Waks AG; Stover DG; Guerriero JL; Dillon D; Barry WT; Gjini E; Hartl C; Lo W; Savoie J; Brock J; Wesolowski R; Li Z; Damicis A; Philips AV; Wu Y; Yang F; Sullivan A; Danaher P; Brauer HA; Osmani W; Lipschitz M; Hoadley KA; Goldberg M; Perou CM; Rodig S; Winer EP; Krop IE; Mittendorf EA; Tolaney SM
Clin Cancer Res; 2019 Aug; 25(15):4644-4655. PubMed ID: 31061067
[TBL] [Abstract][Full Text] [Related]
14. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Martins-Branco D; Nader-Marta G; Molinelli C; Ameye L; Paesmans M; Ignatiadis M; Aftimos P; Salgado R; de Azambuja E
Eur J Cancer; 2023 Nov; 194():113358. PubMed ID: 37857118
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
20. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
